Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Talvey (talquetamab-tgvs) is a bispecific T-cell engaging antibody approved by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Talvey binds simultaneously to GPRC5D, a protein found on multiple myeloma cells, and CD3, a protein on T cells. This dual binding redirects the patient's own T cells to recognize and destroy myeloma cells, offering a novel immune-based approach for heavily pretreated patients.
Talvey is intended for patients with relapsed or refractory multiple myeloma who have exhausted standard treatment options, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies.
Talvey is administered subcutaneously with a step-up dosing schedule to reduce the risk of cytokine release syndrome, followed by either 0.4 mg/kg weekly or 0.8 mg/kg every two weeks as maintenance dosing.
Boxed Warning — Talvey: Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving Talvey. Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), and other serious, life-threatening, or fatal reactions can also occur. Because of these risks, Talvey is available only through a restricted program called the TECVAYLI and TALVEY Risk Evaluation and Mitigation Strategy (REMS).
Patients typically require hospitalization for monitoring during the step-up dosing phase due to the risk of CRS, with close observation for fever, hypotension, and other early warning signs.
Taste changes, dry mouth, and weight loss have been commonly reported, related to Talvey's mechanism affecting GPRC5D-expressing tissue in addition to myeloma cells.
Serious infections and low blood cell counts have been reported. Patients should be monitored closely and managed according to standard supportive care guidelines.
Skin toxicity and liver enzyme elevations have been reported. Talvey may cause fetal harm, and effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Talvey is manufactured and marketed by Janssen. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming multiple myeloma diagnosis and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved bispecific antibody therapy for relapsed or refractory multiple myeloma, Talvey is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Talvey directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Talvey requires refrigerated storage at 2°C to 8°C, protected from light. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Talvey through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Talvey access.
Delhi's major hospitals assist patients with prescription support and documentation for Talvey.
Bangalore's specialist network offers access coordination for eligible multiple myeloma patients seeking Talvey.
Chennai-based hematology specialists coordinate Talvey access alongside comprehensive myeloma care.
Hyderabad's care institutions support patients pursuing Talvey therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Talvey.
Pune-based specialists assist with prescription support and Talvey treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Talvey.
Kochi's specialist units assist patients with the documentation needed for Talvey access.
Chandigarh's care centers support Talvey treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Talvey access process.
Lucknow-based centers assist patients pursuing Talvey therapy.
Bhubaneswar's institutions support access to Talvey for eligible patients.
Guwahati's specialists help coordinate Talvey access for patients across the Northeast.
Patients in other cities across India can also access Talvey through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
